Stockreport

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months [Yahoo! Finance]

Eupraxia Pharmaceuticals Inc.  (EPRX) 
PDF In clinical trials, a single administration of DiffuSphere™ successfully delivered fluticasone propionate for at least six months in patients with eosinophilic esophagi [Read more]